Search

Search Language

italiano / Italian | Use language selector above (below, on mobile) to search additional languages

Open filter

Selected filters
x(Client Results)

14 items matching filters

Search Results

Client Result

Carlyle and SK Capital to Acquire bluebird bio

1 minute read | March.07.2025

bluebird bio announced it will be acquired in a take private transaction by Beacon Parent Holdings, collaborating with Carlyle Group and SK Capital.

Client Result

Weights & Biases to be Acquired by CoreWeave

2 minute read | March.06.2025

Weights & Biases, a leading AI developer platform, announced that it has reached an agreement to be acquired by CoreWeave, the AI Hyperscaler™.

Client Result

Combatting Rare Pediatric Disease: Ipsen to Sell Priority Review Voucher

2 minute read | October.10.2024

Ipsen has agreed to sell its rare pediatric disease priority review voucher to a large global pharmaceutical company for $158 million.

Client Result

Advancing Effective Mental Healthcare: Grow Therapy Raises $88 Million

2 minute read | April.11.2024

Grow Therapy, a provider-centric tech company improving access to high-quality mental healthcare, has closed an $88 million funding round.

Client Result

Ultrafast 3D Printing: Orrick Advises Nexa3D on its Acquisition of Essentium

2 minute read | February.09.2024

Nexa3D, the ultrafast 3D printing leader, has acquired Essentium. Orrick represented Nexa3D.

Client Result

Machine-Learning-Powered Generative Biology: Mirae Asset Group Joins $273M Funding Round for Generate:Biomedicines

2 minute read | September.15.2023

Mirae Asset Global Investments has participated in a $273 million in Series C financing for Generate:Biomedicines.

Client Result

Eli Lilly to Acquire Versanis Bio in up to $1.925 Billion Deal With Potential Implications for Treating Obesity

2 minute read | July.20.2023

Eli Lilly and Company and Versanis Bio have announced a definitive agreement for Lilly to pay up to $1.925 billion in cash to acquire Versanis.

Client Result

Aptean Acquisition of TOTALogistix Enhances its Ability to Help Companies Optimize Logistics

June.13.2023

Orrick advised Aptean in its acquisition of TOTALogistix.

Client Result

Orrick Advises COVA Acquisition on $3.82 Billion SPAC Merger with ECARX

1 minute read | December.20.2022

The merged company will be publicly listed on Nasdaq under the ticker symbol "ECX" with an expected pro forma equity value of approximately $3.82 ...

Client Result

Orrick Advises Kineta on Merger with Yumanity Therapeutics

June.06.2022

ESG: Environmental, Social & Corporate Governance

Under the definitive agreement, Kineta will become a wholly-owned subsidiary of Yumanity in an all-stock transaction.

Client Result

Orrick Advises Fisker on Launch of $350 Million At-the-Market Equity Program

May.24.2022

Orrick advised Fisker in connection with the establishment of its at-the-market equity program.

Client Result

Orrick Advised Catalyst Biosciences on $60 Million Sale of Complement Portfolio

May.24.2022

Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc.